Longterm Dpp4inhibitor Use Not Tied To Fracture Risk In T2dm | Latest News RSS feed

Longterm Dpp4inhibitor Use Not Tied To Fracture Risk In T2dm - Latest News

Long-term DPP4-inhibitor use not tied to fracture risk in T2DM

(HealthDay)—For patients with type 2 diabetes mellitus (T2DM), long-term use of dipeptidyl peptidase-4 inhibitors (DPP4-Is) is not associated with fracture risk, according to a study published online ... read more

Diabetes & Endocrinology News

Medscape Medical News, February 2017 FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes After first rejecting it at the end of 2015, the FDA has now approved the AstraZeneca DPP-4 inhibitor ... read more

Joint Pain Linked to DPP-4 Inhibitor Use by Type 2 Diabetics

(HealthDay News) -- Use of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes is tied to ... about this risk to the labels of all medicines in this drug class." The FDA stressed that ... read more

Looking for another news?

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

Although novel agents have potential advantages including low risk of hypoglycaemia and help with weight control, long-term safety has yet to be ... line pharmacotherapy for patients with T2DM, ... read more

Gastric bypass tied to higher fracture risk versus gastric band

(HealthDay)—There is a 73 percent increased risk for nonvertebral fracture after Roux-en-Y gastric bypass (RYGB) versus adjustable gastric banding (AGB), according to a study published online May 15 ... read more

The role of hormonal treatment in type 2 diabetes mellitus

Long-term complications ... in T2DM in combination with other oral agents. 13 They also exhibit the potential side effects of liver dysfunction, significant weight gain, anemia, and decreased bone ... read more

Ob/Gyn & Women's Health News

IDWeekEfavirenz in Pregnancy Tied to Neurologic Risk in Children ... the use of dolutegravir in women who are or who could become pregnant; it expects to make final recommendations next year. Most ... read more

Bolstering your armamentarium with SGLT2 inhibitors

32 Euglycemic ketoacidosis is considered rare, but recent cases have surfaced both in patients with T1DM and T2DM treated with SGLT2 inhibitors (although these agents are not approved for use in T1DM ... read more

Radiographic Knee OA Tied to Death Risk From Diabetes, Kidney Diseases

is associated with an increased risk for mortality from cardiovascular disease (CVD), diabetes, and renal diseases, but self-reported OA is not, according to a study published in the International ... read more

Merck & Co., Inc. (MRK)

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, ... read more

Alogliptin benzoate for management of type 2 diabetes

Alogliptin benzoate is a newly developed, highly selective DPP-4 inhibitor ... cardiovascular risk with alogliptin in patients with T2DM (hazard ratio, 0.635, 95% CI 0.0–1.41). 66 The results of the ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us